Full-Time
Director Commercial Distribution
Immunome
201-500 employees
Antibody-based therapeutic discovery and development
Compensation Overview
$221.6k - $258.5k/yr
Bothell, WA, USA
Remote
Travel of up to approximately 25% is anticipated.
Bachelor's
 Operations & Logistics (1) |
|---|
Get referred to Immunome
See people who can refer or advise you
- A bachelor's degree is required; an advanced degree is preferred.
- At least 10 years of experience in trade/channel, distribution, or commercial operations in biopharma, with specialty pharmaceuticals experience, or equivalent.
- Experience building and managing specialty distribution networks involving third-party logistics providers, specialty distributors, and specialty pharmacies.
- Strong contract negotiation and partner governance skills, including the ability to interpret common distribution terms and service-level clauses.
- Working knowledge of United States distribution channels and government programs such as 340B, Medicare, and Medicaid, plus experience partnering with Market Access and Patient Services teams.
- Demonstrated ability to track and improve channel performance through metrics and data, including service levels, inventory, order status, and specialty pharmacy data.
- Technology proficiency with Excel, PowerPoint, enterprise resource planning systems, warehouse management systems, third-party logistics systems, and data aggregators.
- Ability to travel as needed to support partner governance, anticipated up to approximately 25%.
- Ability to build productive relationships with diverse internal and external stakeholders.
- Strong organizational, planning, and strategic thinking skills, with the ability to manage competing priorities with urgency and attention to detail.
- Ability to solve problems using data while navigating ambiguity and complexity.
- Strong written, verbal, and presentation skills, including the ability to lead business reviews with senior audiences.
- Hands-on, customer-oriented approach to issue resolution and operational execution.
- High integrity and commitment to compliance, with the ability to escalate appropriately.
- Ability to influence without authority and align cross-functional teams.
- Develop and execute the commercial distribution strategy aligned to access and commercial objectives.
- Design and optimize the distribution network across specialty distributors, wholesalers as applicable, third-party logistics providers, and specialty pharmacies for oral oncology launches and lifecycle changes.
- Own distribution policies and business rules covering eligibility, order limits and allocations, returns, and drug replacement.
- Lead daily distribution operations, monitor order-to-cash activity, and resolve customer onboarding, order approval, shipping exception, inventory constraint, and escalation issues.
- Maintain standard operating procedures and process maps and lead continuous improvement initiatives to strengthen service levels, accuracy, and compliance.
- Partner with Supply Chain and Quality to manage inventory visibility, product release status, recalls, returns, and product integrity requirements.
- Serve as the primary relationship manager for third-party logistics providers, specialty distributors, and network specialty pharmacies.
- Negotiate and govern distribution service agreements and statements of work, define key performance indicators and service-level agreements, and lead quarterly business reviews and corrective action plans with Legal, Compliance, and Finance.
- Own customer master data and class-of-trade governance, including evaluation and approval of new customer requests.
- Ensure compliant distribution operations in accordance with the Drug Supply Chain Security Act, government programs such as 340B, Medicare, and Medicaid, and company policies.
- Oversee distribution data flows and communications, including specialty pharmacy data, inventory and order reporting, pricing compendia, and return-goods policy updates, to enable accurate analytics.
- Partner with Commercial Operations and Information Technology to optimize the commercial systems ecosystem, including data aggregators, the data warehouse, and analytics and business intelligence tools.
- Integrate and govern channel data feeds, track and visualize key performance indicators and service-level agreements, and generate dashboards, scorecards, alerts, actionable insights, and coordinated engagement with field team members and channel customers.
- Establish the long-term vision and operational roadmap for trade and distribution as the portfolio expands.
- Build, develop, and scale internal and external capabilities to support future commercial growth.
- Collaborate with Supply Chain, Finance, Managed Markets, Reimbursement, Patient Services or HUB, Information Technology, Marketing, and Sales or Sales Operations to align channel strategy and execution.
- Support channel financial processes involving fees, reserves, and reconciliations and provide insights on performance and operational opportunities.
- Lead and mentor team members and contractors as appropriate.
- Operate in a fast-paced startup environment.
- Advanced degree.
- Experience with oncology and/or oral oncology.
Immunome identifies antibodies and their targets by studying the immune systems of patients who recover from diseases, to develop first-in-class therapeutics. Its platform analyzes immune responses to discover novel antibodies and their targets, which are then advanced through research and development in partnership with healthcare and medical research clients. The company’s products work by using antibodies discovered from patients’ immune systems to target diseases, potentially enabling new treatments across oncology and other areas. Immunome differentiates itself through a proprietary discovery platform that extracts clinically relevant antibodies from real patient immune responses, enabling collaborations and licensing deals rather than solely pursuing standalone drug sales. The goal is to bring new antibody therapies to patients by forming partnerships, licensing innovations, and eventually delivering approved therapies.
Company Size
201-500
Company Stage
IPO
Headquarters
Bothell, Washington
Founded
2008
Get referred to Immunome
See people who can refer or advise you
Simplify's Take
What believers are saying
- FDA set varegacestat's PDUFA date for April 28, 2027 after strong Phase 3 data.
- Cash and marketable securities totaled $520.0 million on June 30, 2026, funding into 2028.
- IM-1617's first patient dosing on June 11, 2026 expands multiple shots on goal.
What critics are saying
- IM-1617 faces AbbVie's ABBV-400 and Daiichi's crowded TOP1 ADC category by 2027.
- Immunome burned $120.3 million cash in first-half 2026, despite $520.0 million remaining.
- A varegacestat rejection would leave Immunome dependent on early-stage programs and recurring dilution.
What makes Immunome unique
- Varegacestat reached FDA acceptance in July 2026, anchoring Immunome's first near-term asset.
- IM-1617 targets an undisclosed RTK plus immune exclusion, a rare dual-mechanism ADC.
- IM-1021 and IM-3050 broaden the platform across ADC and radioligand modalities.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Hybrid Work Options
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Holidays
Wellness Program
Mental Health Support
Conference Attendance Budget
Professional Development Budget
Stock Options
Company Equity
Phone/Internet Stipend
Home Office Stipend
Growth & Insights and Company News
6 month growth
↑ 21%1 year growth
↑ 21%2 year growth
↑ 9%Immunome reported Q2 2026 financial results, revealing a net loss of $73.1 million. The biotechnology company held $520.0 million in cash, cash equivalents and marketable securities as of 30 June, expected to fund operations into 2028. The FDA accepted Immunome's application for varegacestat, a desmoid tumour treatment, setting an approval decision date of 28 April 2027. Phase 3 trial data showed an 84% reduction in disease progression risk versus placebo. Research and development expenses totalled $59.9 million for the quarter, whilst general and administrative costs reached $18.3 million. Immunome is advancing three additional clinical-stage programmes, with first patients dosed in trials for IM-1617 and IM-3050. The company plans to submit investigational new drug applications for IM-1340 and IM-1335 by late 2026.
Immunome debuts first-in-class ADC targeting mystery immune-excluding receptor tyrosine kinase. June 12, 2026 Bothell, Washington-based Immunome, Inc. (Nasdaq: IMNM) has dosed the first patient in a Phase I first-in-human study of IM-1617, an antibody-drug conjugate directed at an undisclosed receptor tyrosine kinase (RTK) and armed with HC74, the company's proprietary topoisomerase I inhibitor payload. The trial's significance lies partly in its target biology: the RTK in question is described as promoting tumor cell survival while simultaneously mediating immune cell exclusion - a dual role that, if confirmed clinically, could position IM-1617 as relevant in immunologically cold tumors where checkpoint inhibitors have largely failed. The open-label, multicenter dose escalation and expansion study will enroll patients with advanced solid tumors, including colorectal cancer, non-small cell lung cancer, and breast cancer. Primary objectives cover safety, tolerability, and pharmacokinetics, with preliminary anti-tumor activity as an exploratory endpoint. Immunome has not disclosed enrollment targets or an anticipated completion date. Two additional ADC candidates - IM-1340 and IM-1335 - are expected to reach IND submission by mid- and late 2026, respectively, signaling broader platform ambitions beyond this single asset. The rationale for IM-1617 rests on a well-documented but therapeutically underexploited observation: certain receptor tyrosine kinases do not merely sustain tumor cell proliferation but actively remodel the tumor microenvironment to prevent T-cell infiltration. The TAM family RTKs - TYRO3, AXL, and MERTK - are the best-characterized examples, functioning as innate immune checkpoints that suppress dendritic cell and macrophage activity while driving tumor cell survival through PI3K/AKT and RAS/MAPK signaling. AXL in particular has been directly implicated in T-cell exclusion in breast cancer models, where high AXL expression correlated with complete absence of immune infiltration even following radiotherapy. This biology is directly relevant to the three indications Immunome has identified. Approximately 85% of colorectal cancers are microsatellite-stable and immunologically cold, explaining why PD-1/PD-L1 inhibitors have shown no benefit in this population. A comparable subset of non-small cell lung cancers and triple-negative breast cancers similarly fail to respond to immunotherapy, not because of absent antigenicity but because immune cells are physically excluded from the tumor parenchyma. An ADC targeting the RTK responsible for that exclusion could, in principle, simultaneously kill antigen-expressing tumor cells and relieve the suppressive barrier - potentially rendering surviving tumor tissue more susceptible to endogenous or therapeutically induced immune responses. Competitive positioning. The TOP1 inhibitor ADC space is crowded at the payload level but less so at the target level, where differentiation ultimately resides. Daiichi Sankyo and AstraZeneca's DXd platform dominates across HER2, HER3, and TROP2, with multiple Phase II and Phase III assets in NSCLC and breast cancer. AbbVie is advancing ABBV-400, a c-MET-targeted ADC with a proprietary TOP1 inhibitor payload, in NSCLC and colorectal cancer - indications that directly overlap with IM-1617's target population. Because IM-1617's RTK target remains undisclosed, precise competitive mapping is not possible, but the functional description - an RTK driving both survival signaling and immune exclusion - most closely resembles AXL or MERTK biology, neither of which currently has a clinical-stage ADC program of note. Immunome's broader pipeline context is relevant here. Varegacestat, the company's gamma secretase inhibitor for desmoid tumors, has an NDA filed with the US FDA following Phase III data showing 84% reduction in progression risk and a 56% objective response rate - substantially outperforming the current standard. That near-term commercial asset provides a degree of financial and strategic runway for the ADC platform to mature. IM-1021, the ROR1 ADC sharing the HC74 payload with IM-1617, will generate the first human pharmacokinetic and safety data for HC74, which will inform dose selection and linker optimization for subsequent programs including IM-1617. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/
Immunome, a biotechnology company developing targeted cancer therapies, reported first quarter 2026 financial results. The company had cash and cash equivalents of $582.7 million as of 31 March, expected to fund operations into 2028. The company submitted a New Drug Application to the US FDA in April 2026 for varegacestat, a treatment for adults with desmoid tumours. Immunome plans to submit a Marketing Authorisation Application to the European Medicines Agency by year-end 2026. Research and development expenses for the quarter were $46.4 million, whilst general and administrative expenses totalled $13.0 million. Immunome reported a net loss of $53.8 million for the quarter. The company is advancing multiple programmes, including Phase 1 trials for IM-1021 and IM-3050, and recently received IND clearance for IM-1617.
Immunome's Chief Scientific Officer Jack Higgins sold 9,438 shares on 2 April for $204,238, reducing his direct holdings by 30% to 22,000 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan established in December 2025 for financial diversification. The transaction comes as the clinical-stage biotechnology company approaches a significant milestone: its lead candidate varegacestat met the primary endpoint in a Phase 3 trial in December 2025, with an FDA submission planned for the second quarter of 2026. Immunome expects three additional investigational new drug applications and early data from IM-1021 across 2026. The company's stock has risen 250% over the past year, bringing its market capitalisation to $2.40 billion.
Immunome has reported a reduced full-year net loss of $212.39 million for 2025 and filed a $156.03 million common stock shelf registration linked to an employee stock option plan offering. The biotechnology company also updated investors on progress in its oncology pipeline. The company plans to file a New Drug Application for varegacestat following positive Phase 3 data, with multiple solid tumour investigational new drug applications also in development. However, Immunome remains deeply unprofitable despite the narrower losses. The shelf registration raises concerns about potential equity dilution and ownership overhang. Fair value estimates from analysts vary widely, ranging from approximately $29 to over $215 per share, reflecting significant uncertainty around the company's prospects as it advances its high-risk oncology platform.